Finally, 77 cases of intrahepatic cholangiocarcinoma (ICC) were collected for verification. Cholangiocarcinoma is the second most common primary malignant liver tumor. The incidence rate and mortality ...

in managing advanced intrahepatic cholangiocarcinoma (ICC). Methods: A retrospective analysis of treatment data for patients with advanced ICC who received ICIs at the Second Affiliated Hospital of ...

Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Some researchers have recommended that although the diagnosis of cholangiocarcinoma should ... we present 24 patients with intrahepatic bile duct dilation and no mass lesion demonstrated on ...

The Bismuth–Corlette classification system provides an anatomic description of the tumor location and longitudinal extension in the biliary tree (Figure 3). It is limited due to its failure to ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

Hepatocellular carcinoma is the most common form of liver cancer. It can begin as a single tumor or multiple small tumors throughout the liver. Intrahepatic Cholangiocarcinoma A cancerous tumor in the ...

TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3 ...